News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
Augurex to Exhibit at CCR East 2026
Vancouver, Canada – April 16, 2026 Augurex Life Sciences Corp., a leader in the development of autoimmune diagnostic tests, today announced it will attend and exhibit at the Congress of Clinical Rheumatology (CCR) East 2026, taking place April 30 to May 3 in Destin,...
Augurex Named ADLM 2026 Disruptive Technology Award Semifinalist
Vancouver, Canada – April 14, 2026 – Augurex Life Sciences Corp., a leader in the development of autoimmune-based diagnostics, today announced that it has been named a semifinalist in the 2026 Disruptive Technology Award competition presented by the Association for...
Augurex to Attend and Present Data at the British Society for Rheumatology 2026 Annual Meeting
Vancouver, Canada – April 8, 2026 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced it will attend and present new data at the British Society for Rheumatology (BSR) 2026 Annual Meeting, taking place April 28–30 in Glasgow,...
Augurex Featured as a Top 5 JPM Interview on NPR’s BioTech Nation
January 12, 2026 - Augurex was featured by Moira Gunn of NPR’s BioTech Nation as one of her Top 5 interviews for the J.P. Morgan Healthcare Conference.Listen to the interview here: You’ve Had Back Pain for 7-10 Years? Neil Klompas, CEO, AugurexThe BioTech Nation Top 5...
SAA Publishes New Article and Features Augurex’s ACR 2025 Findings in eSUN Newsletter
Dec 3, 2025 – The Spondylitis Association of America (SAA) has published a new article and featured Augurex’s latest data from the American College of Rheumatology (ACR) 2025 conference in their eSUN newsletter.Read the full article on the SAA website: New Research...
Neil Klompas Featured on the Progress, Potential, and Possibilities Podcast
November 25, 2025 – Neil Klompas, CEO and President of Augurex, was featured on the Progress, Potential, and Possibilities Podcast, hosted by Dr. Ira Pastor.🎧 Listen to the full episode:In the episode “Ending Diagnostic Delays in Autoimmune Conditions,” Neil discusses...
Dr. Norma Biln joins the Spondycast to discuss SPINEstat® and the future of axSpA diagnosis
November 21, 2025 – Dr. Norma Biln, Augurex Co-founder and Chair of the Board, was featured on the Spondycast Podcast, hosted by the Spondylitis Association of America.🎧 Listen to the full Spondycast episode:In Episode 121: Closing the Diagnosis Delay in...
Augurex Life Sciences Corp. Announces the Launch of the 14-3-3eta Test for Rheumatoid Arthritis Diagnosis and Monitoring with Sonic Reference Laboratory
Augurex expands its 14-3-3eta test availability through a new partnership with Sonic Reference Laboratory, a division of Sonic Healthcare USA, to enhance the diagnosis and management of rheumatoid arthritis. The 14-3-3eta test will launch at Sonic Reference Laboratory...
RheumNow Highlights Anti-14-3-3eta Multiplex Data in ACR 2025 Coverage: Biomarker Discovery in axSpA
Vancouver, Canada – October 31, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that RheumNow, a leading rheumatology news platform, has featured Augurex’s latest ACR Convergence 2025 data on the Anti-14-3-3eta...
Augurex Featured as a Top 5 JPM Interview on NPR’s BioTech Nation
January 12, 2026 - Augurex was featured by Moira Gunn of NPR’s BioTech Nation as one of her Top 5 interviews for the J.P. Morgan Healthcare Conference.Listen to the interview here: You’ve Had Back Pain for 7-10 Years? Neil Klompas, CEO, AugurexThe BioTech Nation Top 5...
SAA Publishes New Article and Features Augurex’s ACR 2025 Findings in eSUN Newsletter
Dec 3, 2025 – The Spondylitis Association of America (SAA) has published a new article and featured Augurex’s latest data from the American College of Rheumatology (ACR) 2025 conference in their eSUN newsletter.Read the full article on the SAA website: New Research...
Neil Klompas Featured on the Progress, Potential, and Possibilities Podcast
November 25, 2025 – Neil Klompas, CEO and President of Augurex, was featured on the Progress, Potential, and Possibilities Podcast, hosted by Dr. Ira Pastor.🎧 Listen to the full episode:In the episode “Ending Diagnostic Delays in Autoimmune Conditions,” Neil discusses...
Dr. Norma Biln joins the Spondycast to discuss SPINEstat® and the future of axSpA diagnosis
November 21, 2025 – Dr. Norma Biln, Augurex Co-founder and Chair of the Board, was featured on the Spondycast Podcast, hosted by the Spondylitis Association of America.🎧 Listen to the full Spondycast episode:In Episode 121: Closing the Diagnosis Delay in...
RheumNow Highlights Anti-14-3-3eta Multiplex Data in ACR 2025 Coverage: Biomarker Discovery in axSpA
Vancouver, Canada – October 31, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that RheumNow, a leading rheumatology news platform, has featured Augurex’s latest ACR Convergence 2025 data on the Anti-14-3-3eta...
RheumNow’s ACR 2025 coverage highlights Augurex’s data on Anti-14-3-3eta Multiplex Immunoassay Test
Vancouver, Canada – 28 October, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that RheumNow, a leading rheumatology news platform, has featured Augurex’s latest ACR Convergence 2025 data on the Anti-14-3-3eta...
Augurex Life Sciences Granted FDA Breakthrough Designation for SPINEstat®, its First-in-Class Diagnostic Test for Axial Spondyloarthritis
The U.S. FDA has granted Breakthrough Device Designation to SPINEstat® (14-3-3eta Autoantibody Multiplex Immunoassay Test), recognizing its potential to address a significant unmet need in the diagnosis of patients with axial spondyloarthritis (axSpA). SPINEstat®,...
AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA)
Vancouver, Canada – October 22, 2025 — Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA)....
Take a Pain Check Foundation features a new blog highlighting Augurex’s 14-3-3eta biomarker
Take a Pain Check Foundation features a new blog highlighting Augurex’s 14-3-3eta biomarker. The blog post explores how biomarkers improve diagnosis and personalized care in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Vancouver, Canada – June 5,...
Augurex to Exhibit at CCR East 2026
Vancouver, Canada – April 16, 2026 Augurex Life Sciences Corp., a leader in the development of autoimmune diagnostic tests, today announced it will attend and exhibit at the Congress of Clinical Rheumatology (CCR) East 2026, taking place April 30 to May 3 in Destin,...
Augurex Named ADLM 2026 Disruptive Technology Award Semifinalist
Vancouver, Canada – April 14, 2026 – Augurex Life Sciences Corp., a leader in the development of autoimmune-based diagnostics, today announced that it has been named a semifinalist in the 2026 Disruptive Technology Award competition presented by the Association for...
Augurex to Attend and Present Data at the British Society for Rheumatology 2026 Annual Meeting
Vancouver, Canada – April 8, 2026 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced it will attend and present new data at the British Society for Rheumatology (BSR) 2026 Annual Meeting, taking place April 28–30 in Glasgow,...
Augurex Life Sciences Corp. Announces the Launch of the 14-3-3eta Test for Rheumatoid Arthritis Diagnosis and Monitoring with Sonic Reference Laboratory
Augurex expands its 14-3-3eta test availability through a new partnership with Sonic Reference Laboratory, a division of Sonic Healthcare USA, to enhance the diagnosis and management of rheumatoid arthritis. The 14-3-3eta test will launch at Sonic Reference Laboratory...
Augurex to Exhibit and Present New Data on Anti-14-3-3eta Multiplex in Axial Spondyloarthritis at ACR Convergence 2025
Vancouver, Canada – October 17, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that it will be exhibiting at Booth 919 and presenting new data at the American College of Rheumatology (ACR) Convergence 2025, taking...
Augurex Announces Expansion of Availability of the JOINTstat® Diagnostic Test for Rheumatoid Arthritis with MitogenDx
Augurex has partnered with MitogenDx to expand access to JOINTstat® testing across Canada, improving physician and patient access to advanced tools for rheumatoid arthritis (RA) diagnosis and monitoring. JOINTstat® is a Health Canada-approved Class II in vitro...
Augurex Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
Augurex to present new data from clinical studies in an oral presentation and two poster presentations at ACR Convergence 2025, taking place October 24 – 29 in Chicago, IL. Professor Raj Sengupta will present new data in on the use of autoantibodies to 14-3-3eta in...
Augurex to Exhibit and Present New Data at CCR West 2025
Vancouver, Canada – September 8, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced it will exhibit and present new data at the Congress of Clinical Rheumatology West (CCR West) 2025, taking place September 18–21 in...
Augurex to Exhibit and Sponsor Industry Lunch Seminar at the AMLI 2025 Annual Meeting
Vancouver, Canada – August 5, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Association of Medical Laboratory Immunologists (AMLI) 38th Annual Meeting, taking place August 14–17 at the Hyatt...
Home
Products
Science
About
News
Careers
Contact